Received by email:
File: PRESS RELEASE - IMAGIN MEDICAL RESEARCH STUDY BEGINS - FINAL -1-22-18.pdf
IMAGIN MEDICAL RESEARCH STUDY BEGINS
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will
establish a new standard of care for urologists in detecting cancers and visualizing the
surgical field in minimally invasive surgery. The Company's initial focus is bladder cancer.
______________________________________________________________________________________________________________________
--->________________________________________________________________________________
Vancouver, B.C. and Boston, MA, January 22, 2018 Imagin Medical (CSE: IME)
(OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the "Company"), as a
follow-up to the announcement dated November 29, released additional information
concerning the research study using the i/Blue Imaging System being conducted at
the University of Rochester Medical Center.
As of today, initial subjects have been recruited and procedures are being
coordinated with the lead investigator's surgical schedule. During the 10-subject
research study, Imagin's development team will work with the surgical staff to
evaluate outcomes and adjust system components as needed to optimize product
performance. "We are excited to see the study underway and are fortunate to be
working with the University of Rochester, one of the nation's leading academic
medical centers, on this important step forward for Imagin," said Jim Hutchens,
Imagin's President and CEO.
Demonstrating feasibility of the technology and defining the parameters for success
will be followed by thorough assessment and refinement of all components for
technical and cost efficiency. Progress will be reported as information becomes
available. Imagin anticipates all ten procedures will be completed within four months,
with the study remaining open for an additional nine months for subject follow-up.
All updates will be published by the University of Rochester on www.clinicaltrials.gov
according to the Research Study Guidelines.
The purpose of the study is to validate previous bench-testing results that showed
the i/Blue Imaging System technology will enable physicians to "see" the cancer in
less than 15 minutes vs. the full hour required by today's technology, as well as
blend the white and florescence images into one, placing the cancer in context within
the bladder. For further information on the study, visit, Near Infrared Fluorescence
Imaging for Bladder Cancer Detection.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer during
minimally invasive surgeries. The Company believes it will radically improve the way
physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer
worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due
to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National
Laboratory, this advanced, ultrasensitive imaging technology is based upon improved
optical designs and advanced light sensors. Learn more at www.imaginmedical.com.
For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com
Information set forth in this news release contains forward-looking statements. These statements
reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees
of future performance. The Company cautions that all forward-looking statements are inherently
uncertain and that actual performance may be affected by a number of material factors, many of
which are beyond the Company's control. Accordingly, actual and future events, conditions and
results may differ materially from the estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. Specifically, there is no assurance the Company's imaging
system will work in the manner expected, except as required under applicable securities legislation;
the Company undertakes no obligation to publicly update or revise forward-looking information. The
CSE has neither approved nor disapproved the information contained herein and does not accept
responsibility for the adequacy or accuracy of this news release.
_______________________________________________________________________________
U.S. HQ: CA HQ:
69 Longwood Avenue 890 West Pender Street, Suite 600
Hyannis Port, MA 02647 Vancouver, British Columbia
USA Canada V6C 1J9
617-571-6006 778-998-5000; 604-687-1327 (fax)
NR-2018-IME-#04
File: PRESS RELEASE - IMAGIN MEDICAL RESEARCH STUDY BEGINS - FINAL -1-22-18.docx
IMAGIN MEDICAL RESEARCH STUDY BEGINS
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care
---> for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company's i
--->nitial focus is bladder cancer. ______________________________________________________________________________________
--->________________________________________________________________________________________________________________
Vancouver, B.C. and Boston, MA, January 22, 2018 - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart
--->Symbol: DPD2) (the "Company"), as a follow-up to the announcement dated November 29, released additional information c
--->oncerning the research study using the i/Blue Imaging System being conducted at the University of Rochester Medical Ce
--->nter.
As of today, initial subjects have been recruited and procedures are being coordinated with the lead investigator's su
--->rgical schedule. During the 10-subject research study, Imagin's development team will work with the surgical staff to
--->evaluate outcomes and adjust system components as needed to optimize product performance. "We are excited to see the s
--->tudy underway and are fortunate to be working with the University of Rochester, one of the nation's leading academic m
--->edical centers, on this important step forward for Imagin," said Jim Hutchens, Imagin's President and CEO.
Demonstrating feasibility of the technology and defining the parameters for success will be followed by thorough asses
--->sment and refinement of all components for technical and cost efficiency. Progress will be reported as information bec
--->omes available. Imagin anticipates all ten procedures will be completed within four months, with the study remaining o
--->pen for an additional nine months for subject follow-up. All updates will be published by the University of Rochester
--->on www.clinicaltrials.gov according to the Research Study Guidelines.
The purpose of the study is to validate previous bench-testing results that showed the i/Blue Imaging System technolog
--->y will enable physicians to "see" the cancer in less than 15 minutes vs. the full hour required by today's technology,
---> as well as blend the white and florescence images into one, placing the cancer in context within the bladder. For fur
--->ther information on the study, visit, Near Infrared Fluorescence Imaging for Bladder Cancer Detection.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer during minimally invasive surgeries.
--->The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bla
--->dder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due t
--->o a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasen
--->sitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginm
--->edical.com.
For further information, contact: Jim Hutchens, President & CEO Telephone: 617-571-6006 Email: jhutchens@imaginmed
--->ical.com
Information set forth in this news release contains forward-looking statements. These statements reflect management's
--->current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company ca
--->utions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a n
--->umber of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, con
--->ditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implie
--->d in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in t
--->he manner expected, except as required under applicable securities legislation; the Company undertakes no obligation t
--->o publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information
--->contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
_______________________________________________________________________________
U.S. HQ:
69 Longwood Avenue
CA HQ:
890 West Pender Street, Suite 600
Hyannis Port, MA 02647
Vancouver, British Columbia
USA
Canada V6C 1J9
617-571-6006
778-998-5000; 604-687-1327 (fax)
NR-2018-IME-#04
© 2024 Canjex Publishing Ltd. All rights reserved.